Article (Scientific journals)
Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study.
CANTON, Rafael; LVERMORE, David M; MOROSINI, Maria Isabel et al.
2016In Journal of Antimicrobial Chemotherapy
Peer Reviewed verified by ORBi
 

Files


Full Text
J. Antimicrob. Chemother.-2016-Cantón-jac_dkw442.pdf
Publisher postprint (173.21 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Ceftaroline; MIC; Etest; Broth microdilution; Staphylococcus aureus
Abstract :
[en] OBJECTIVES: To compare the concordance of ceftaroline MIC values by reference broth microdilution (BMD) and Etest (bioMérieux, France) for MSSA and MRSA isolates obtained from PREMIUM (D372SL00001), a European multicentre study. METHODS: Ceftaroline MICs were determined by reference BMD and by Etest for 1242 MSSA and MRSA isolates collected between February and May 2012 from adult patients with community-acquired pneumonia or complicated skin and soft tissue infections; tests were performed across six European laboratories. Selected isolates with ceftaroline resistance in broth (MIC >1 mg/L) were retested in three central laboratories to confirm their behaviour. RESULTS: Overall concordance between BMD and Etest was good, with >97% essential agreement and >95% categorical agreement. Nevertheless, 12 of the 26 MRSA isolates found resistant by BMD scored as susceptible by Etest, with MICs ≤1 mg/L, thus counting as very major errors, whereas only 5 of 380 MRSA isolates found ceftaroline susceptible in BMD were miscategorized as resistant by Etest. Twenty-one of the 26 isolates with MICs of 2 mg/L by BMD were then retested twice by each of three central laboratories: BMD MICs of 2 mg/L were consistently found for 19 of the 21 isolates. Among 147 Etest results for these 21 isolates (original plus six repeats per isolate) 112 were >1 mg/L. CONCLUSIONS: BMD and Etest have good overall agreement for ceftaroline against Staphylococcus aureus; nevertheless, reliable Etest-based discrimination of the minority of ceftaroline-resistant (MIC 2 mg/L) MRSA is extremely challenging, requiring careful reading of strips, ideally with duplicate testing.
Research center :
CIRM - Centre Interdisciplinaire de Recherche sur le Médicament - ULiège
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
CANTON, Rafael;  Hospital Universitario Ramo ́n y Cajal and Instituto Ramo ́n y Cajal de Investigacio ́n Sanitaria (IRYCIS), Madrid, Spain > Servicio de Microbiologıa
LVERMORE, David M;  University of East Anglia, Norwich, UK > Norwich Medical School
MOROSINI, Maria Isabel;  Hospital Universitario Ramo ́n y Cajal and Instituto Ramo ́n y Cajal de Investigacio ́n Sanitaria (IRYCIS), Madrid, Spain > Servico de microbiologia
DIAZ-REGANON, Jazmin;  AstraZeneca, Madrid, Spain > Medical Department,
ROSSOLINI, Gian Maria;  University of Florence and Careggi University Hospital, Florence, Italy > Department of Experimental and Clinical Medicine > Clinical Microbiology and Virology Unit
MELIN, Pierrette  ;  Centre Hospitalier Universitaire de Liège - CHU > Service de microbiologie clinique
PREMIUM STUDY GROUP, Several collaborators including P. MELIN;  Belgium, Italy, Portugal, Spain, Switzerland, UK
Language :
English
Title :
Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study.
Publication date :
20 October 2016
Journal title :
Journal of Antimicrobial Chemotherapy
ISSN :
0305-7453
eISSN :
1460-2091
Publisher :
Oxford University Press, London, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
AstraZeneca [BE]
Available on ORBi :
since 19 December 2016

Statistics


Number of views
135 (4 by ULiège)
Number of downloads
98 (2 by ULiège)

Scopus citations®
 
16
Scopus citations®
without self-citations
16
OpenCitations
 
15

Bibliography


Similar publications



Contact ORBi